Cardiome sees in New Year with glad tidings from Merck
This article was originally published in Scrip
Cardiome Pharma, the Canadian biotech company, says it has received seasonal cheer about its oral vernakalant mixed ion channel antagonist programme from its partner Merck & Co. The news that the US pharma had completed its review of the oral formulation of the atrial fibrillation (AF) compound and plans to move forward with clinical development in 2011 will be a relief to Cardiome's shareholders. Indeed, the company's share price advanced 9.2% to $6.55 on 30 December.